DOCSLIB.ORG

Chapter 6 Industrial Applications of Multicomponent Reactions (Mcrs)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chapter 6 Industrial Applications of Multicomponent Reactions (Mcrs) University of Groningen Innovative multicomponent reactions and their use in medicinal chemistry Zarganes Tzitzikas, Tryfon IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2017 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Zarganes Tzitzikas, T. (2017). Innovative multicomponent reactions and their use in medicinal chemistry. University of Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 CHAPTER 6 INDUSTRIAL APPLICATIONS OF MULTICOMPONENT REACTIONS (MCRS) Chapter contained in the Rodriguez-Bonne book Stereoselectve Multple Bond-Forming Transformatons in Organic Synthesis 2015 by John Wiley & Sons, Inc. Tryfon Zarganes – Tzitzikas, Ahmad Yazbak, Alexander Dömling Chapter 6 INTRODUCTION Multcomponent reactons (MCRs) can be defned as processes in which three or more reactants introduced simultaneously are combined through covalent bonds to form a single product, regardless of the mechanisms and protocols involved.[1] Many basic MCRs are name reactons, for example, Ugi,[2] Passerini,[3] van Leusen,[4] Strecker,[5] Hantzsch,[6] Biginelli,[7] or one of their many variatons. Several descriptve tags are regularly atached to MCRs they are atom economic, for example, the majority if not all of the atoms of the startng materials are incorporated in the product; they are efcient, for example, they efciently yield the product since the product is formed in one-step instead of multple sequental steps; they are convergent, for example, several startng materials are combined in one reacton to form the product; they exhibit a very high bond-forming-index (BFI), for example, several non-hydrogen atom bonds are formed in one synthetc transformaton. Since MCRs are ofen highly compatble with a range of unprotected orthogonal functonal groups, on a second level, the scafold diversity of MCR can be greatly enhanced by the introducton of orthogonal functonal groups into the primary MCR product and react them in subsequent transformatons, e.g. ring forming reactons. This two layered strategy has been extremely fruitul in the past leading to a great manifold of scafolds now routnely used in combinatorial and medicinal chemistry for drug discovery purposes.[8] A versatle example of this strategy are the Ugi-Deprotecton-Cyclizaton procedures (UDC) leading to a great scafold diversity, e.g. benzimidazoles, benzodiazepinedione, tetrazolodiazepinone, quinoxalinones, γ-lactams, and piperazines.[9] Similarly multple bond-forming transformatons (MBFTs) require the involvement of substrates exhibitng multple potental reacton sites and the selectve control of their reactvity in each individual bond-forming event. Some classes of densely functonalized small molecules have been shown to be partcularly suited for use in these transformatons, and in this context, 1,2- and 1,3-dicarbonyl compounds are exceptonal synthetc platorms.[10] The rapid and easy access to biologically relevant compounds by MCRs and their scafold diversity has recognized them by the synthetc community in industry and academia as a preferred method to design and discover biologically actve compounds. Although the list of MCR applicatons towards the synthesis of marketed drugs or drugs under development is much longer we will focus and discuss in the following chapters eight recent examples. 140 Industrial applicatons of multcomponent reactons (MCRs) APPLICATIONS OF MCRS Xylocaine The reacton of isocyanides, oxo components, and primary or secondary amines yields α-amino carbonamides, as disclosed by Ugi in 1959. The reacton has been employed by Ugi early on to synthesize the local anesthetc Xylocaine (Scheme 1).[11] It clearly shows the genius of Ivar Ugi who recognized the important applicatons of MCR chemistry several decades before the area of combinatorial chemistry was born. Xylocaine alters depolarizaton in neurons, by blocking the fast voltage gated sodium (Na+) channels in the cell membrane. While there are many synthetc approaches towards Xylocaine such as the one in (Scheme 1) Ugi’s approach is amongst the shortest and without doubts the most convergent and diverse one. e.g. many newer derivatves of the same class of anesthetcs can be synthesized by the same route by simple variaton of the three startng material classes, amine, oxo and isocyanide components (Scheme 2). 6 Scheme 1. Synthesis of Xylocaine Almorexant Almorexant is a frst-in-class orexin receptor antagonist that was undergoing phase III clinical development for insomnia untl 2011. The tetrahydroisoquinoline derivatve was originally discovered from a series of Ugi/Pictet−Spengler reacton products. Originally developed by Actelion, from 2007 Almorexant was being reported as a potental blockbuster drug, as its novel mechanism of acton (orexin receptor antagonism) was thought to produce beter quality sleep and fewer side efects than the traditonal benzodiazepine and z-drugs, that dominate the mult- billion dollar insomnia medicaton market. [12] 141 Chapter 6 Scheme 2. Derivatves of Xylocaine Figure 1 . Structure of Almorexant The discovery synthesis of Almorexant starts with an Ugi three-component reacton (Ugi-3CR) between benzaldehyde (4), 2-(3,4-dimethoxyphenyl)ethanamine (5) and methyl isocyanide (6) afording product 7, which in a post Pictet−Spengler reacton with 3-(4-(trifuoromethyl)phenyl) propanal (8) in the presence of strongly acidic conditons gives the end product Almorexant (9). Clearly, the synthesis is not stereoselectve and yields four diferent stereoisomers of which only one is biologically highly actve (Scheme 3). 142 Industrial applicatons of multcomponent reactons (MCRs) Scheme 3. Discovery synthesis of Almorexant involving a one pot Ugi-3CR and Pictet-Spengler-2CR reacton Lefort et al. reported on two new efcient catalytc systems for the enantoselectve synthesis of intermediate 10 needed for the synthesis of Almorexant (Scheme 4).[13] The frst one relies on an asymmetric hydrogenaton of 11 using an iridium complex with a ferrocene-based ligand while the second one relies on an asymmetric transfer hydrogenaton of 11 using a ruthenium catalyst with a diamine ligand. Both catalysts were studied further and appeared to be suited for large- scale manufacturing (Scheme 5). In case Almorexant had not been stopped from phase III clinical development in 2011, a fnal choice would have been guided mainly by the cost of goods for the two routes, considering the availability of the producton units and the delivery tme of the raw materials. 6 Scheme 4. Almorexant and its key intermediate 143 Chapter 6 Scheme 5 . Asymmetric hydrogenaton of 11 with Ir/TaniaPhos and asymmetric transfer hydrogenaton with Noyori catalyst towards 10 Interestngly TaniaPhos catalysts used in the asymmetric hydrogenatons can be synthesized from the (R)-Ugi amine 15 in two steps.[14] The (R)-Ugi amine can be synthesized via a Mannich reacton between ferrocene 12, dimethyl amine (13) and acetaldehyde (14) (Scheme 6).[15] Scheme 6. Synthesis of (R)-Ugi amine 144 Industrial applicatons of multcomponent reactons (MCRs) (−)-Oseltamivir (Tamilfu®) New infectous diseases appear regularly in diverse parts of the globe, most recently swine fu, creatng new global health threats. The upcoming of new multple drug resistance seasonal fu and infectous and deadly infuenza pandemics in regular intervals of 20-40 years is of great concern. Current weaponry to fght infuenza can only build on a handful of chemotherapeutc optons besides immunizaton. While immunizaton is suitable to control seasonal fu it is not believed to work with new fu pandemics. The antinfuenza neuraminidase inhibitor (−)-oseltamivir is one of the few remaining chemotherapy optons and has been recently synthesized by the Hayashi group by a remarkably short and high yielding asymmetric synthesis (Scheme 7).[16] The synthesis consists of a one-pot MCR involving the Michael reacton of α-alkoxyaldehyde (16) and cis- nitroalkene 17, catalyzed by (S)-diphenylprolinol silyl ether (18), proceeded in the presence of HCO2H in chlorobenzene to aford the Michael product 19 in good yield with excellent diastereo and enantoselectvity. Ethyl acryl derivatve 20 and Cs2CO3 were added to the same pot generatng the desired product 21 and two diferent intermediates which were later converted into 21 by the additon of EtOH. In the next step the Michael reacton of toluenethiol (22), followed by epimerizaton at the α-positon of the nitro group, aforded the thiol Michael adduct 23a with the desired stereochemical confguraton. By additon of Zn and TMSCl to the same vessel, reducton of the nitro group gave the amine 23b, from which a retro-Michael reacton of the thiol group proceeded by treatment with base to aford Oseltamivir (Tamilfu®)
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0065361A1 Deshmukh Et Al
    US 2005OO65361A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0065361A1 Deshmukh et al. (43) Pub. Date: Mar. 24, 2005 (54) PROCESS FOR PREPARING ALKYLARYL (22) Filed: Sep. 22, 2003 CHLOROFORMATES Publication Classification (76) Inventors: Abdul Rakeeb Abdul Subhan Deshmukh, Maharashtra (IN); Vikas (51) Int. Cl." ........................... C07C 69/74; C07C 69/96 Kalyanrao Gumaste, Maharashtra (IN) (52) U.S. Cl. .............................................................. 558/280 Correspondence Address: (57) ABSTRACT NIXON & VANDERHYE, PC The present invention discloses an improved method for the 1100 N GLEBE ROAD preparation of alky/aryl chloroformates directly from alco 8TH FLOOR hols and triphosgene. This method is simple, mild and ARLINGTON, VA 22201-4714 (US) efficient avoids use of hazardous phosgene. It can be used for the preparation of various aryl as well as alkyl chlorofor (21) Appl. No.: 10/665,410 mates in excellent yields. US 2005/0065361 A1 Mar. 24, 2005 PROCESS FOR PREPARING ALKYLARYL Maligres, K. C. Nicolau, W. Wrasidio Bioorg. Med. Chem. CHLOROFORMATES Lett. 1993, 3, 1051. (c) D. C. Horwell, J. Hughes, J. Hunter, M. C. Pritchard, R. S. Richardson, E. Roberts, G. N. FIELD OF THE INVENTION Woodruff J. Med. Chem., 1991, 34, 404 and tertiary amines as base H. Eckert, B. Forster, Angew. Chem. Int. Ed. Engl., 0001. The present invention relates to a process for 1987,26,894). Hydroquinone is also used in the preparation preparing alkyl/aryl chloroformates. More particularly, the of chloroformates from triphosgene G. Van den Mooter, C. present invention relates to a process for preparing com Samyn, R. Kinget Int. J. Pharm., 1993, 97, 133).
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • The Preparation of Certain Organic Chloroformates and Carbonates
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 1947-04-01 The preparation of certain organic chloroformates and carbonates Robert E. Brailsford Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd BYU ScholarsArchive Citation Brailsford, Robert E., "The preparation of certain organic chloroformates and carbonates" (1947). Theses and Dissertations. 8175. https://scholarsarchive.byu.edu/etd/8175 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. THE PREPARATI OH OF CERTAI N 0RG.1NIC CHLOROFORJ.'\Ll.TES AND CARBON T Thesis ubmitted to the Department of Chemistry Brigham Young University ~ .. ... "') .~ . ~ . "'). ... .. .. .. .. , ... .. ... : : ....: . ..-. ~ ..·.: : ..: ...• : ·.. ~ . : ,.. .~ : :. : ·: : ··.... ; ~ : ·. : : .: . : . : : : ••• .... •." •,.r_·: -••• ~ .... In Parti a l Fulfillment of the Re~uirements for the Degree Master of cienoe 147143 by Robert E. Brailsford .tipril 1947 This Thesis by Robert E. Brailsford is accepted in its present farm by the Department of Chemistry of Brigham Young University as satisfying the ·rhesis requirement for the degree of Master of Science. PREFACE flhile working for the Hooker Electrochemical Company of Niagara Falls , New York , from April 3 , 1943 , to January 30 , 1946 , the writer became interested in organic chloroformates and. carbonates , an interest instigated by requests from B. F . Goodrich Company for a number of samples . fter returning to Brigham Young University that preliminary interest was revived and the experi - mental work of this thesis was performed. under the direction of Dr . Charles ' . :Maw and Professor Joseph K.
    [Show full text]
  • Carbonate and Benzyl Benzotriazol-L-Yl Carbonate. Now
    70 Bull. Korean Chem. Soc., Vol. 7, No. 1, 1986 Sunggak Kim and Heung Chang t-Butyl Benzotriazol-l-yl Carbonate and Benzyl Benzotriazol-l-yl Carbonate. Now Reactive Amino Protective Reagents for t-Butoxy carbonylation and Benzyloxycarbonylation of Amines and Amino Acids Sunggak Kim* and Heung Chang Department of Chemistry, Korea Advanced Institute of Science and Technology, Seoul 131, Received September24,1985 New amino protective reagents, /-butyl benzotriazol-l-yl carbonate and benzyl benzotriazol-l-yl carbonate, for t~ butoxycarbonylation and benzyloxycarbonylation of amines and amino acids have been developed. f-Butyl benzotriazol-1 -yl carbonate reacts rapidly and cleanly with various amines and amino acids to afford N-Boc amines and N-Boc amino acids in high yields and benzyl benzotriazol-l-yl carbonate is also found to be very effective in the benzyloxycarbonylation of amino acids. Introduction a solution of an equimolar amount of 1-hydroxybenzotriazole and pyridine in methylene chloride to the solution of an ex­ The Z-butoxycarbonyl (Boc) group is one of the most im­ cess amount of phosgene in toluene under cooling portant amino protective groups along with benzyloxycarbonyl (-20~ 一 10°C). The resulting product was relatively unstable (Cbz) group in peptide synthesis.1 Since /-butyl chloroformate and was mainly decomposed to 1-hydroxybenzotriazole dur­ is only fairly stable above 10°C,2 it is difficult to is이 ate t- ing workup with cold water. Thus； benzotriazol-l-yl chlorofor­ butyl chloroformate as a pure form in high yields. Thus, con­ mate was used in a crude form. BBC could be prepared readily siderable efforts have been devoted to the development of a by the reaction of benzotriazol-l-yl chloroformate with variety of useful and reliable reagents for the preparation of equimolar amounts of f나 mtyl alcohol and pyridine in N-Boc amino acids during last 30 years.1 methylene chloride at room temperature for 2 h (eq.
    [Show full text]
  • FOGSI FOCUS PTL-Final
    Editors : President: Jaideep Malhotra Dr. Rishma Dhillon Pai Narendra Malhotra Contributors Preface Dr. Asha Reddy Dr. Ruchika Garg, Assistant Professor obs. & gynae, Dr. Apoorva Pallam Reddy, SN Medical College, Agra Consultant Preterm Labour is one of the 5 ‘P’ problem of pregnancy. Dr. Rajalaxmi Walavalkar, Dr. Anuradha Khar, Senior consultant, Cocoon fertility centre, Despite of understanding the problem, the prevalence is static Director, nurture IVF, Bangalore Thane even in developed countries. Dr. Arshi Iqbal, Dr. Raju Sahetya, Director Arshi fertility, Kota, Consultant obs. and gynae, Hinduja The problem of being born to soon is more in babies born Rajasthan Hospital, Mumbai before 33 weeks gestation and babies born in developing countries with low resource settings. Dr. Chaitanya Ganapule, Dr. Rakhi Singh, Pearl IVF, Pune Director Abalone clinic and IVF centre, Noida This multiauthored FOGSI focus is a comprehensive Dr. Kavita N Singh, collection of all aspects of Preterm Labour. The authors have Associate Professor, NSCB Medical Dr. Shalini Chauhan, done a great job in rehearsing each topic and compiling College, Jabalpur Assistant Professor, PGI Tanda relevant information which will be useful to the practising Dr. Kavitha Gautam, Dr. Seema Pandey, obstetrician. Director Bloom fertility, Chennai Director Seema Hospital and Eva fertility centre, Azamgarh Dr. Neema Acharya, We hope all FOGSIANS will benefit from this manuscript. Professor, DMIMS DU, Wardha Dr. Swati Upadhyay, SR KIMS, Trivendrum Dr. Niharika Malhotra Happy Reading Dr. Uma Pandey, Dr. Parul Mittal, specialist obs. & gynae, Professor obs. & gynae, IMS BHU, Aster D.M. Healthcare, Dubai, UAE Varanasi Jaideep Malhotra, Narendra Malhotra Dr. Paresh K Solanki Dr.
    [Show full text]
  • Benzyl Chloroformate (CHLOROFORMIC ACID, BENZYL ESTER)
    Rev B Benzyl Chloroformate (CHLOROFORMIC ACID, BENZYL ESTER) C8H7O2Cl Molecular Weight = 170.6 CAS# 501‐53‐1 SPECIFICATIONS Assay: 98.% min. Color (APHA): 50 max. Benzyl Alcohol: 0.1% max. Hydrogen Chloride: 0.1% max. Benzyl Chloride: 1.5% max. Phosgene: 0.1% max. Dibenzyl Carbonate: 0.5% max. Iron: 1.5 PPM max. PHYSICAL PROPERTIES Appearance: Clear liquid free of visible contaminants BP: Decomposes at elevated temperature Odor: Pungent Density: 1.195 ‐1.22 MP/Range: ‐30°C Flash Point: 126°C NOTICE: The technical information and suggestions for use made herein are based on VanDeMark’s research and experience and are believed to be reliable, but such information and suggestions do not constitute a warranty, and no patent liability can be assumed. This publication is not to be taken as a license to operate under or infringe on any patents. Since VanDeMark has no control over the conditions under which the product is transported, stored, handled, used or applied, buyer must determine for himself by preliminary tests or otherwise, the suitability of the product for his purposes. VanDeMark’s liability on any basis is limited to the price of the product used. The information in this bulletin supersedes all previously issued bulletins on the subject matter covered. VanDeMark Benzyl Chloroformate APPLICATIONS SPILLS AND DISPOSAL Benzyl Chloroformate is a reactive chemical intermediate Use personal protective equipment (see MSDS). used in the synthesis of pharmaceutical and agrochemical Evacuate personnel to safe areas. Dike far ahead of products. It is used as a reagent in peptide synthesis to liquid spill for later disposal.
    [Show full text]
  • Synthesis, Utility and Medicinal Importance of 1,2- & 1,4
    RSC Advances REVIEW View Article Online View Journal | View Issue Synthesis, utility and medicinal importance of 1,2- & 1,4-dihydropyridines Cite this: RSC Adv.,2017,7, 2682 Vivek K. Sharmaa and Sunil K. Singh*b Dihydropyridine (DHP) is among the most beneficial scaffolds that have revolutionised pharmaceutical research with unprecedented biological properties. Over the years, metamorphosis of easily accessible 1,2- and 1,4-dihydropyridine (1,4-DHP) intermediates by synthetic chemists has generated several drug molecules and natural products such as alkaloids. The 1,4-dihydropyridine (1,4-DHP) moiety itself is the main fulcrum of several approved drugs. The present review aims to collate the literature of 1,2- and the 1,4-DHPs relevant to synthetic and medicinal chemists. We will describe various Received 6th October 2016 methodologies that have been used for the synthesis of this class of compounds, including the Accepted 14th November 2016 strategies which can furnish enantiopure DHPs, either by asymmetric synthesis or by chiral resolution. DOI: 10.1039/c6ra24823c We will also elaborate the significance of DHPs towards the synthesis of natural products of medicinal www.rsc.org/advances merit. Creative Commons Attribution 3.0 Unported Licence. 1. Introduction oxidation–reduction reactions, has made the 1,4-DHP core even more lucrative. Perhaps less studied in the past, the potential of Arthur Hantzsch added one of the most valuable scaffolds to the 1,2-dihydropyridines has recently been explored as a critical toolbox of medicinal chemists, reporting the synthesis of scaffold for the synthesis of alkaloids and other drugs. 1,2-DHPs dihydropyridine (DHP) in 1882.
    [Show full text]
  • Oxytocin Receptor OXTR
    Oxytocin Receptor OXTR The oxytocin receptor belongs to the G-protein-coupled seven-transmembrane receptor superfamily. Its main physiological role is regulating the contraction of uterine smooth muscle at parturition and the ejection of milk from the lactating breast. The oxytocin receptors are activated in response to binding oxytocin and a similar nonapeptide, vasopressin. Oxytocin receptor triggers Gi or Gq protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions. Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. In vivo, oxytocin acts as a paracrine and/or autocrine mediator of multiple biological effects. These effects are exerted primarily through interactions with G-protein-coupled oxytocin/vasopressin receptors, which, via Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides. www.MedChemExpress.com 1 Oxytocin Receptor Agonists & Antagonists Atosiban Atosiban acetate (RW22164; RWJ22164) Cat. No.: HY-17572 (RW22164 acetate; RWJ22164 acetate) Cat. No.: HY-17572A Atosiban (RW22164; RWJ22164) is a nonapeptide Atosiban acetate (RW22164 acetate;RWJ22164 competitive vasopressin/oxytocin receptor acetate) is a nonapeptide competitive antagonist, and is a desamino-oxytocin analogue. vasopressin/oxytocin receptor antagonist, and is a Atosiban is the main tocolytic agent and has the desamino-oxytocin analogue. Atosiban is the main potential for spontaneous preterm labor research. tocolytic agent and has the potential for spontaneous preterm labor research. Purity: 99.09% Purity: 99.92% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Carbetocin Epelsiban Cat.
    [Show full text]
  • Synthetic Methods for Biologically Relevant Organofluorine Compounds
    Scholars' Mine Doctoral Dissertations Student Theses and Dissertations Spring 2007 Synthetic methods for biologically relevant organofluorine compounds Meher Perambuduru Follow this and additional works at: https://scholarsmine.mst.edu/doctoral_dissertations Part of the Chemistry Commons Department: Chemistry Recommended Citation Perambuduru, Meher, "Synthetic methods for biologically relevant organofluorine compounds" (2007). Doctoral Dissertations. 2286. https://scholarsmine.mst.edu/doctoral_dissertations/2286 This thesis is brought to you by Scholars' Mine, a service of the Missouri S&T Library and Learning Resources. This work is protected by U. S. Copyright Law. Unauthorized use including reproduction for redistribution requires the permission of the copyright holder. For more information, please contact [email protected]. t+/ E. : i :_~· f 9;?.::; SYNTHETIC METHODS FOR BIOLOGICALLY RELEVANT ORGANOFLUORINE COMPOUNDS by MEHERPERAMBUDURU A DISSERTATION Presented to the Faculty ofthe Graduate School of the UNIVERSITY OF MISSOURI-ROLLA In Partial Fulfillment of the Requirements for the Degree DOCTOR OF PHILOSOPHY m CHEMISTRY 2007 V. PRAKASH REDDY EKKEHARD SINN ~~ NURANERCAL 111 ABSTRACT This thesis describes novel synthetic methodologies for the synthesis of biologically relevant organofluorine compounds. Chapter 1 outlines the recent trends in this area and our synthetic procedures for the preparation of the gem-difluoromethylene analogues of the biologically active dipeptides, carnosine and carcinine. Synthesis of the latter compounds has been achieved using the fluorinated building block approach. Thus reaction of gem-difluoro-~­ alanine with histidine methyl ester dihydrochloride or histamine dihydrochloride using N­ benzyloxycarbonyl (N-Cbz) protecting strategy and EDCVHOBt peptide coupling protocol gave the gem-difluorinated version of the peptides carnosine and carcinine respectively. The gem­ Difluoro analogue of ~-alanine was prepared from a fluorine synthon, ethyl bromodifluoroacetate using Reforrnatsky reaction conditions.
    [Show full text]
  • AY Thesis Version 16 4 05 Final Printed for Binding
    Fluorescent cannabinoids: Strategies towards the synthesis of fluorescently labelled CB2 receptor ligands Andrew Stephen Yates BPharm MRPharmS AMRSC School of Pharmacy, The University of Nottingham Nottingham UK Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy November 2004 1 “A chemist dabbling in his lab Felt his project was a little drab So embarked to discover fluorescent weed Citing a greater scientific need Soon had friends with glowing lips Funded his life on their grateful tips Checked his spectra, in disbelief When his friends got no relief He made an error in his reaction That gave his friends no satisfaction In desperation he hid away Improving his creation day by day His project done, his girlfriend’s plea Was to write it up as a PhD This is what I submit to you To read, to marvel, to hold as true” - A. S. Yates 2 Table of contents Abstract ...........................................................................................................................i Acknowledgements ........................................................................................................ii Abbreviations ................................................................................................................iii 1. Introduction............................................................................................................1 1.1 Fluorescent labelled ligands as a tool to study G-protein coupled receptors.2 1.1.1 Principles of fluorescence ......................................................................4
    [Show full text]
  • Documents Numérisés Par Onetouch
    19 ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE 51 8 Inter. CI. C07D 471/04 (2018.01) 11 A61K 31/519 (2018.01) N° 18435 A61P 29/00 (2018.01) A61P 31/12 (2018.01) A61P 35/00 (2018.01) FASCICULE DE BREVET D'INVENTION A61P 37/00 (2018.01) 21 Numéro de dépôt : 1201700355 73 Titulaire(s): PCT/US2016/020499 GILEAD SCIENCES, INC., 333 Lakeside Drive, 22 Date de dépôt : 02/03/2016 FOSTER CITY, CA 94404 (US) 30 Priorité(s): Inventeur(s): 72 US n° 62/128,397 du 04/03/2015 CHIN Gregory (US) US n° 62/250,403 du 03/11/2015 METOBO Samuel E. (US) ZABLOCKI Jeff (US) MACKMAN Richard L. (US) MISH Michael R. (US) AKTOUDIANAKIS Evangelos (US) PYUN Hyung-jung (US) 24 Délivré le : 27/09/2018 74 Mandataire: GAD CONSULTANTS SCP, B.P. 13448, YAOUNDE (CM). 45 Publié le : 15.11.2018 54 Titre: Toll like receptor modulator compounds. 57 Abrégé : The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido [3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them. O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected] 18435 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application Nos. 62/128397, filed March 4, 2015, and 62/250403, filed November 3, 2015, both of which are incorporated herein in their entireties for all purposes.
    [Show full text]
  • Thesis of Substituted Hydroxyguanidines and Related Systems
    University of Bath PHD Synthesis of substituted hydroxyguanidines and related systems. Peace, Alastair Award date: 1983 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 04. Oct. 2021 TO MY FAMILY AND JACQUELINE ^ __ 2 8 MAR 1933 Synthesis of Substituted Hydroxyguanidines and Related Systems. Submitted by Alastair Peace for the degree of Ph.D of the University of Bath 1983. COPYRIGHT Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults i t is understood to recognise that its copyright rests with its author and that no quotation from the thesis, and no information derived from i t may be published with­ out the prior written consent of the author.
    [Show full text]